Updated on 7 August 2014
Jubilant said that performance was affected due to extended plant shut-down in CMO business to address USFDA issues
India: The board of Jubilant Life Sciences, an integrated pharmaceutical and lifesciences company met on August 06, 2014 to approve financial results for the quarter ended June 30, 2014.
Commenting on the company's performance, Mr Shyam S Bhartia, chairman and managing director and Mr Hari S Bhartia, co-chairman and managing director, Jubilant Life Sciences said, "Performance of the quarter was affected due to extended plant shut-down in CMO business to address USFDA issues. These operations have now normalized, and along with new product introductions and strategic initiatives, should deliver strong performance in our Pharmaceutical operations. In Lifescience ingredients, we witnessed growth across all businesses aided by price and volume gains. We are confident that we have laid the foundation for a strong performance in the remaining quarters of the year."
Q1 FY2015 Highlights
· Consolidated revenue at Rs 1,473 Crore, grew 8 percent YoY
· International revenues at Rs 1,051crore, contributed 71 percent to the overall mix